Amid lawsuits from pharmaceutical manufacturers and a new HHS administration, the 340B Program faces an uncertain future. For pharmacy leaders, the unpredictability of reimbursements impacts your ability to care for patients, your supply chain operations, and your financial outcomes. In this session, we will cut through the uncertainty and review the outlook of 340B Program, including the current status of litigation and the Biden administration’s actions to date. We’ll also offer strategies to reduce the impact of these reimbursement uncertainties.
- Analyze strategies to plan for and manage reimbursement uncertainties.
- Explain the status of litigation and its impact on pharmacy leaders.
- Outline the Biden administration’s position and actions surrounding the 340B Program.